AbbVie collaboration boosts Halozyme stock
This article was originally published in Scrip
Executive Summary
AbbVie is paying oncology-focused biotech Halozyme Therapeutics $23m upfront, and up to $130m in potential milestone payments for each of up to nine collaboration targets, in order to get access to the company's Enhanze drug delivery platform.
You may also be interested in...
Halozyme's 2017 Includes PEGPH20 Milestones, New Partnership
Halozyme CEO Helen Torley spoke with Scrip about execution of the company's strategy – reworked after her arrival in 2014 – to focus on oncology drug development and partnerships using its Enhanze platform.
In Vivo’s Deals Of The Year 2020: Winners Revealed
For In Vivo's 13th annual Deals of the Year contest, we selected 15 nominees in three categories – Top Alliance, Top Financing and Top M&A. The polls are closed, and it is time to reveal the winners.
Direct To Consumer Approach Underscores Femtech’s Disruptive Potential
A new technology accelerator, FemTech Lab, will support the scale-up of at least 10 firms in 2021 that have innovative solutions for issues affecting women’s health and wellbeing. The founders talk to In Vivo about their view of the femtech market and how it will impact traditional health care.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: